Jon R Adkins, 63Baltimore, MD

2021038, Dec 9, 2021

Jun 3, 2021

17/337786

- Boston MA, US
- Enfield NH, US
Andrey PTITSYN - Revere MA, US
Elizabeth CHANG - Pittsford NY, US
Jon ADKINS - Londonderry NH, US
Travis BROWN - Columbia MO, US
Kaitlyn ROGERS - Madisonville LA, US

XENOTHERAPEUTICS, INC. - Boston MA
XENOTHERAPEUTICS CORPORATION - Enfield NH

G16B 35/20
G16B 5/20
G16B 40/00
C12N 15/10
G16H 50/20
G16H 50/70
G16H 70/60
G16H 10/60
G16H 10/40
G06N 20/00

A method for predictive engineering of a sample derived from a genetically optimized non-human donor suitable for xenotransplantation into a human having improved quality or performance is provided. The method includes constructing a training data set from a series of libraries, wherein at least one library in the series of libraries comprises genomic, proteomic, and research data specific to non-humans. The method includes developing a predictive machine learning model based on the constructed training data set. The method includes utilizing the predictive machine learning model to obtain a predicted quality or performance of a plurality of sequences for a candidate sample from the non-human donor specific to a human patient or patient population. The method includes selecting a subset of sequences for evaluation from the plurality of sequences based on the predicted quality or performance. The method includes designing candidate samples derived from the non-human donor using the selected subset of sequences. The method includes measuring a respective in silico performance of each designed candidate sample. The method includes selecting a designed candidate sample for manufacture based on the respective in silico performance of each designed candidate sample.

2020010, Apr 9, 2020

Oct 4, 2019

16/593785

- Boston MA, US
Jon ADKINS - Londonderry NH, US
Rodney L. MONROY - North Fort Myers FL, US
Elizabeth J. CHANG - Pittsford NY, US

XenoTherapeutics, Inc. - Boston MA

A61L 27/36

A biological product for clinical xenotransplantation into a human and a method of preparing biological product for clinical xenotransplantation into a human involving producing a non-wild type, biologically engineered swine having a biologically engineered genome such that the swine does not express one or more extracellular surface glycan epitopes, is free of certain pathogens, is reared according to a bioburden-reducing procedure in a closed designated pathogen free herd, wherein the biological product is harvested following the swine being euthanized and the product is aseptically removed from the swine, the biological product is processed involving sterilization and storing the product in a sterile container, and the product does not contain one or more extracellular surface glycans, is free of certain designated pathogens, is biologically active and comprises live cells and tissues capable of vascularizing after xenotransplantation.